Arcus Biosciences Inc.公布最新临床数据,在对四个单药治疗队列进行的汇总分析中,患者的中位无进展生存期为12.2个月,18个月里程碑式无进展生存率达到43%。
Arcus Biosciences Inc.公布最新临床数据,在对四个单药治疗队列进行的汇总分析中,患者的中位无进展生存期为12.2个月,18个月里程碑式无进展生存率达到43%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.